Aurobindo Pharma intimated a board meeting on May 21, 2026, to approve audited standalone and consolidated financial results for Q4 and FY ended March 31, 2026.
The disclosure is made pursuant to Regulation 29 of the SEBI Listing Obligations and Disclosure Requirements Regulations, 2015.
The company's trading window, closed since April 1, 2026, will remain shut until May 23, 2026, and reopen on May 24, 2026.